Venmax drugs & pharmaceuticals Limited has filed its mandatory annual declaration with BSE confirming that promoters have not encumbered any shares during the financial year ended March 31, 2026. The disclosure was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance Declaration

The company submitted the declaration on April 6, 2026, through Company Secretary and Compliance Officer Priyanka Agarwal. The filing confirms that the promoters and promoter group have maintained their shareholdings without any encumbrance throughout the financial year.

Promoter Share Declaration

Promoter Venkat Narender Nuka provided a specific declaration regarding his shareholding in the company. His disclosure was addressed to both BSE and the company's Audit Committee, ensuring comprehensive regulatory compliance.

Regulatory Framework

The SEBI (Substantial Acquisition of Shares and Takeovers) Regulations mandate annual declarations from promoters to ensure transparency in shareholding patterns. Under Regulation 31(4), promoters must declare any encumbrance on their shares, while Regulation 31(5) requires disclosure of changes in encumbrance status.

The declaration serves as a compliance measure to maintain market transparency and protect investor interests. Both the company and individual promoter have fulfilled their regulatory obligations by confirming no encumbrance was created on promoter shares during the specified period.

Venmax drugs & pharmaceuticals Limited has strengthened its board of directors with two strategic appointments announced following a board meeting held on March 30, 2026. The pharmaceutical company disclosed these developments in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Appointments Overview

The board meeting, which commenced at 4:00 P.M and concluded at 5:00 P.M on March 30, 2026, resulted in the approval of two key director appointments based on recommendations from the Nomination and Remuneration Committee.

Director Profile: Mrs. Padmaja Kalyani Sadhanala

Mrs. Padmaja Kalyani Sadhanala brings significant expertise to the board with her Post Graduate qualification in Genetics and Cell Biology. She possesses over 20 years of experience in the pharmaceutical industry, making her well-suited for the company's operations. Notably, she is the spouse of the Managing Director of the company. Her appointment as Additional Director will be effective until the conclusion of the next General or Annual General Meeting, after which she will be eligible for appointment as a regular Director.

Director Profile: Mr. Revoor Ramachandra

Mr. Revoor Ramachandra comes with extensive industrial experience spanning more than 42 years across Defence, Aerospace, and Automotive components industries. His educational background includes a B.E (Mechanical) from B.M.S. College of Engineering and an M.B.A. from Central College, Bangalore, affiliated to Bangalore University, with specialization in Production and Materials Management. He has been appointed for a five-year term as an Independent Director and has no relationship with any existing directors of the company.

Regulatory Compliance and Next Steps

Both appointments are subject to approval by the company's members at the next General or Annual General Meeting. The company has confirmed that neither appointee is debarred from holding director positions by SEBI or any other regulatory authority. No managerial remuneration has been specified for either position at this time.

The appointments reflect the company's commitment to strengthening its governance structure with experienced professionals from relevant industry backgrounds, particularly in pharmaceutical and industrial sectors.